

Patent Claims

- 5 Sub 1. 7
- 10 1. Process for the production of an orally administrable multiple-unit sustained-release dose formulation having controlled agitation-independent release, characterized in that the hydrophilic polymer HPC having an average molecular weight of 250 000 to 1 200 000 is combined in an amount from 40 to 95% by weight, based on the active compound-polymer mixture and a molar degree of substitution of at least 3, as a release-sustaining erosion material, with at least one pharmaceutical active compound and this active compound-polymer combination is converted into small particles having a diameter of 0.2 to 3.0 mm and these are used in the production of active oral administration forms and finished medicaments.
- 15 2. Process for the production of a formulation according to Claim 1, characterized in that HPC is employed in an amount from 45 to 90% by weight.
- 20 3. Process for the production of a formulation according to Claim 1, characterized in that HPC having an average molecular weight of 350 000 to 1 150 000 is employed.
- 25 4. Process for the production of a formulation according to Claim 1, characterized in that the active compound-polymer combination is converted into small particles having a maximum diameter of 0.5 to 2 mm.
- 30 5. Process for the production of formulations according to Claim 1, characterized in that the particles for the active compound-polymer combination are produced by melt extrusion and granulation.
6. Process for the production of formulations according to Claim 1, characterized in that the particles of the active compound-polymer combination are produced by conventional tableting methods.

- 5 7. Process for the production of formulations according to Claim 1, characterized in that the active compound-polymer combination particles are produced in the form of pellets, granules, minitables or grains and these are filled into capsules in an efficacious dosage.
- 10 8. Process for the production of formulations according to Claim 1, characterized in that the active compound-polymer combination particles are additionally lacquered.
- 15 9. Use of HPC having an average molecular weight of 250 000 to 1 200 000 in the production of agitation-independent pharmaceutical sustained-release preparations, obtainable according to Claim 1.
- 20 10. Use of HPC having an average molecular weight of 350 000 to 1 150 000 as main sustained-release polymer and, if appropriate, small amounts of further hydrophilic polymers such as polymethacrylic esters in the production of agitation-independent sustained-release preparations according to Claim 1.
- 25 11. Use of active compound-polymer combination particles according to Claim 1 for the production of finished medicaments in the form of capsules or tablets.
12. Orally administrable multiple-unit sustained-release dose formulations having controlled agitation-independent release obtainable according to Claim 1.